News Articles

<< Previous Page  Displaying 9 through 16 of 73  Next Page >>
Exciting partnership to advance precision medicine for LRRK2!
Monday, February 5, 2018
Parkinson's Institute and Clinical Center Collaborates with Merck to Evaluate LRRK2 Kinase Inhibition in Preclinical Model of Parkinson's Disease Sunnyvale, CA January 29, 2018...The Parkinson's Institute and Clinical Center has entered into a collaboration with Merck, known as MSD outside the United States and Canada, to study the effects of LRRK2 kinase
The Parkinson's Institute & Clinical Center and NeuraMetrix, Inc. announced that the Parkinson's Institute & Clinical Center has been elected to the Scientific Advisory Board of NeuraMetrix, Inc.
Monday, November 20, 2017
“The Parkinson’s Institute and Clinical Center is renowned and highly regarded throughout the medical community as a premiere center for excellence in patient care and research,” says Jan Samzelius, CEO, NeuraMetrix. “We welcome Dr. Barlow to our Scientific Advisory Board and are pleased to further our relationship with the
Chrono Therapeutics and the Parkinsonís Institute and Clinical Center announced today the formation of a strategic alliance focused on collaborating on how medicine is delivered to Parkinsonís patients.
Monday, October 23, 2017
The collaboration focuses on understanding the latest methods in delivering needed drugs to Parkinson’s patients transdermally. "This is a unique opportunity for a leading biopharmaceutical company and a world-renowned research institute to combine forces to make a significant impact on Parkinson’s,” said Dr. Carrolee Barlow, CEO
Thank you to our More Talk! More Walk! & Parkinsonís Battle of the Bay sponsors!
Wednesday, February 1, 2017
Thank you to our early Parkinson’s Battle of the Bay sponsors! UCB Acadia Amedisys Adamas Parkinson’s Institute & Clinical Center highly appreciates the support of our sponsors. It is through their efforts that Your Institute can further provide breakthroughs in Parkinson’s disease research aimed to close the gap between
Parkinson's Institute receives $1.9 million from the California Institute for Regenerative Medicine
Wednesday, January 25, 2017
The California Institute for Regenerative Medicine has made a $1.9 million grant to the Institute for Dr. Birgitt Schuele, MD, Associate Professor, Program Director of Gene Discovery and Stem Cell Modeling to study the effects of downregulation of a key protein implicated in Parkinson’s disease as a potential novel gene therapy approach.
Parkinsonís Institute and Clinical Center partners with CENTOGENE to characterize Parkinsonís patients with targeted gene panel
Thursday, January 12, 2017
For the first time, ever, the Parkinson’s Institute and Clinical Center and CENTOGENE have entered into a collaboration aimed at genetic screening of a large cohort of Parkinson’s patients in the US. Now, individual patients will be screened using a large customized panel carefully selected to identify pathophysiological relevant genetic
The Parkinsonís Institute Is Offering A Six-Week Fitness Program Featuring OhioHealth Delay The Disease
Friday, September 2, 2016
This group exercise program is expressly designed for people with Parkinson’s Disease. Delay The Disease is an evidenced-based wellness program that empowers people with PD to live a more active lifestyle. The program is designed with symptom-specific exercises that optimize function and restore independence. Created by leading Parkinson’s
Friday, January 15, 2016
Sunnyvale, CA, January 15, 2016----The Parkinson’s Institute and Clinical Center announces their partnership with Global Kinetics Corporation (GKC) in a pilot program that will provide Institute patients with access to an innovative mobile health technology. The Personal KinetiGraph™ (PKG™) is a wrist-worn device that offers comprehensive,
<< Previous Page  Next Page >>
2500 Hospital Drive, Bldg #10, Suite 1 | Mountain View, CA 94040
650.770.0201 main | 650.770.0204 fax (Clinic Secure)